YOLFTbeta
Alterity Therapeutics Ltd

Alterity Therapeutics Ltd

ATHE · NASDAQ · Healthcare / Biotechnology

1.96USD-0.14 (-6.44%)

Price History

Full chart

Market Stats

Previous Close2.10
Open2.04
Day Range1.70 – 2.14
52-Week Range2.66 – 5.89
Volume109.70K
Market Cap66.82M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.95
Dividend Yield0.00%
Beta-0.04
50-Day Avg4.43
200-Day Avg4.03

About

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. David A. Stamler M.D.
  • Employees11
  • Headquarters500 Collins Street, Melbourne, VIC, Australia, 3000, USA
  • Websitehttps://alteritytherapeutics.com

Leadership

  • Dr. David A. Stamler M.D.CEO & Director · b. 1961
  • Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO & Company Secretary · b. 1983
  • Dr. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of Research & Development Advisory Board · b. 1959
  • Dr. Steven D. Targum M.D.Chief Medical Advisor
  • Dr. Robert ChernyHead of Research

Financials

Income Statement

Currency: AUD1998-06-301999-06-302000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue--78.76K516.18K794.39K1.81M2.31M2.64M762.49K507.04K492.00K428.19K215.01K156.13K186.66K150.87K363.77K176.84K142.66K132.40K201.17K108.54K411.57K4.34M5.12M3.92M4.02M5.44M0
Growth (%)---+555.40%+53.90%+127.98%+27.39%+14.53%-71.14%-33.50%-2.97%-12.97%-49.79%-27.38%+19.55%-19.18%+141.12%-51.39%-19.33%-7.19%+51.95%-46.05%+279.19%+954.41%+18.06%-23.56%+2.63%+35.32%-100.00%
Cost of Revenue-------------399.24K267.88K-4.34M-7.85M257.30K22.81K21.33K21.80K29.70K112.43K360.03K364.67K285.07K214.30K127.52K113.01K
Gross Profit--78.76K516.18K794.39K1.81M2.31M2.64M762.49K507.04K492.00K428.19K215.01K-243.10K186.66K4.49M8.21M-80.46K119.85K111.07K179.38K78.84K-112.43K3.98M4.76M3.63M3.80M5.31M-113.01K
Gross Margin--100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%-155.70%100.00%2975.15%2256.66%-45.50%84.01%83.89%89.16%72.64%-27.32%91.70%92.88%92.72%94.67%97.66%-
Operating Expense--421.93K3.52M5.79M5.60M11.20M14.45M12.18M11.50M13.23M8.72M5.12M6.03M5.51M12.29M20.76M10.36M8.71M6.99M7.95M12.79M10.30M19.16M20.26M18.27M23.41M19.89M27.69M
Operating Income-690-80.00K-343.18K-3.00M-5.00M-3.79M-8.89M-11.81M-11.41M-10.99M-12.73M-8.29M-4.90M-6.28M-5.32M-7.80M-12.55M-10.44M-8.59M-6.88M-7.77M-12.71M-10.41M-15.18M-15.50M-14.64M-19.60M-14.57M-27.80M
Operating Margin---435.73%-581.36%-628.85%-209.40%-385.32%-446.85%-1496.86%-2167.55%-2588.19%-1935.69%-2279.38%-4020.25%-2849.27%-5171.41%-3450.60%-5901.05%-6019.19%-5197.94%-3862.48%-11713.74%-2530.33%-349.77%-302.56%-373.72%-487.69%-267.96%-
EBITDA-690-80.00K-343.18K-1.86M-3.83M-2.61M-7.70M-15.95M-12.12M-10.93M-12.68M-7.49M-4.87M-6.40M-5.21M-7.76M-12.53M-10.57M-8.56M-6.86M-11.37M-12.77M-13.34M-15.16M-17.39M-14.60M-19.57M-14.63M-27.69M
EBITDA Margin---435.73%-360.38%-482.67%-144.11%-333.83%-603.48%-1589.56%-2156.00%-2577.46%-1748.88%-2265.79%-4096.36%-2790.20%-5144.36%-3444.51%-5979.88%-6003.20%-5181.83%-5651.68%-11761.54%-3242.33%-349.34%-339.46%-372.75%-486.94%-269.05%-
Net Income-690-80.00K-1.33M-4.14M-5.45M-4.57M-9.83M-24.91M-11.73M-11.14M-13.59M-7.52M-4.91M-6.43M-5.24M-7.79M-13.33M-5.89M-7.73M-7.54M-8.27M-11.96M-10.06M-15.31M-12.85M-13.81M-19.12M-12.15M-22.89M
Net Income Margin---1684.00%-801.84%-686.23%-252.40%-425.88%-942.61%-1537.92%-2197.05%-2762.17%-1756.87%-2282.20%-4118.99%-2806.90%-5161.66%-3664.14%-3327.87%-5418.28%-5696.60%-4108.75%-11020.84%-2444.24%-352.78%-250.75%-352.54%-475.79%-223.35%-
R&D--421.93K2.38M2.48M1.86M5.20M7.66M7.62M4.49M5.77M2.22M87.99K2.33M4.23M7.95M14.91M12.30M9.59M5.70M6.70M12.98M10.10M12.28M14.75M13.20M18.64M14.40M17.24M
R&D as % of Total Revenue--535.73%460.38%312.35%102.47%225.42%289.76%999.06%885.77%1172.68%517.37%40.92%1491.97%2265.42%5266.89%4098.16%6954.32%6719.17%4305.52%3329.46%11961.88%2453.56%283.06%287.81%337.01%463.86%264.84%-
Interest Expense00000000000003.76K11.54K17.68K29.98K00000002.50K----
Interest Expense % of Total Revenue--0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%2.41%6.18%11.72%8.24%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.05%----

Balance Sheet

Currency: AUD1998-06-301999-06-302000-06-302001-06-302002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets199.28K1.84M20.88M22.29M17.59M16.34M41.16M22.20M10.43M7.72M11.72M4.60M6.80M9.01M7.34M17.07M41.64M41.83M33.73M25.28M18.73M19.91M13.30M33.59M41.36M27.32M19.22M46.03M46.02M
Total Liabilities199.96K1.92M147.14K894.58K912.82K564.54K2.70M2.68M1.69M2.11M1.84M847.43K1.57M2.08M1.72M3.10M3.95M2.72M2.36M1.59M2.64M3.36M2.76M3.12M5.89M4.50M5.43M3.62M3.29M
Total Equity-670-80.67K20.73M21.39M16.68M15.78M38.47M19.51M8.73M5.61M9.89M3.75M5.23M6.93M5.62M13.97M37.69M39.11M31.37M23.69M16.08M16.55M10.55M30.47M35.47M22.81M13.80M42.40M42.73M
Cash20204.47M6.85M3.59M3.45M29.40M21.37M10.02M7.41M11.24M4.30M5.23M8.84M5.64M13.35M34.17M34.91M28.59M21.88M15.24M14.40M9.20M28.12M34.81M15.77M12.64M33.16M37.32M
Total Debt-------------285.79K299.01K802.64K--000033.75K65.65K117.49K210.38K159.04K155.46K193.47K
Net Debt-20-20-4.47M-6.85M-3.59M-3.45M-29.40M-21.37M-10.02M-7.41M-11.24M-4.30M-5.23M-8.55M-5.34M-12.54M-34.17M-34.91M-28.59M-21.88M-15.24M-14.40M-9.16M-28.05M-34.69M-15.56M-12.48M-33.00M-37.13M

Cash Flow

Currency: AUD2002-06-302003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-3.77M-3.58M-5.31M-11.37M-11.66M-9.20M-9.41M-6.99M-4.71M-4.56M-6.85M-7.95M-13.79M-10.87M-7.42M-5.87M-6.25M-13.95M-9.43M-17.33M-12.34M-20.04M-12.61M-11.45M-22.03M
Investing Cash Flow-84.28K-87.67K-133.55K-50.26K-55.28K-4.26K-81.95K-36.19K-22.67K-16.36K-26.76K-28.15K-23.05K-182.83K-833-27.92K-18.42K-7.02K-16.74K-10.47K-89.15K-36.46K-5.72K-7.50M7.34M
Financing Cash Flow580.65K3.56M31.59M4.69M-2.02K7.37M13.75M100.81K5.66M8.34M3.62M15.58M35.21M6.84M152.60K-159.56K-107.68K12.72M3.98M36.69M16.30M124.34K9.22M39.67M18.71M
Capital Expenditure84.28K87.67K133.55K50.26K55.66K4.56K46.71K36.19K22.67K13.69K26.76K22.00K23.05K28.76K2.31K27.92K62.41K7.02K16.74K10.47K89.15K7.31K5.72K322.03M
Free Cash Flow-3.85M-3.67M-5.45M-11.42M-11.71M-9.20M-9.46M-7.03M-4.73M-4.57M-6.87M-7.97M-13.81M-10.90M-7.42M-5.89M-6.31M-13.96M-9.45M-17.34M-12.43M-20.04M-12.61M-11.45M-22.52M
Dividends Paid-------------000000000---
FCF to OCF102.24%102.45%102.51%100.44%100.48%100.05%100.50%100.52%100.48%100.30%100.39%100.28%100.17%100.26%100.03%100.48%101.00%100.05%100.18%100.06%100.72%100.04%100.05%100.00%102.23%
Dividend Paid to FCF-------------0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%---

Earnings

Report DateDec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Feb 26, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Aug 25, 2015Dec 31, 2015Feb 29, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Feb 24, 2017Jun 30, 2017Aug 31, 2017Dec 31, 2017Feb 28, 2018May 30, 2018Aug 31, 2018Nov 28, 2018Feb 28, 2019May 29, 2019Aug 30, 2019Nov 27, 2019Feb 27, 2020Jun 3, 2020Aug 27, 2020Dec 2, 2020Feb 25, 2021Jun 2, 2021Aug 30, 2021Dec 1, 2021Feb 28, 2022Jun 1, 2022Aug 30, 2022Nov 30, 2022Mar 2, 2023May 31, 2023Feb 28, 2025Aug 28, 2025Aug 27, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.00-8.400.000.000.000.000.000.000.000.000.00-5.580.000.000.000.000.00-0.540.000.000.000.000.00-0.280.00-0.270.00-0.360.00-0.400.000.000.000.000.00-0.170.000.000.00-0.240.00-1.800.00-0.11-0.67-
EPS Actual-0.01-0.01-0.01-0.01-0.01-0.00-0.00-0.01-0.01-0.01-0.00-0.01-0.01-0.01-0.01-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.01-0.00-0.01-0.00-0.01-0.00-0.26-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.130.000.000.00-0.240.000.000.000.000.00-
Surprise---------99.94%---------99.97%-----98.15%-----98.71%-98.67%-99.39%-99.35%-----22.35%---0.00%-100.00%-100.00%100.00%-
Timing---------After-hours---------After-hours----------------------------------

Key Statistics & Ratios

Market Cap66.82M
Enterprise Value40.42M
Trailing P/E0.00
Forward P/E0.00
Price / Sales18.51
Price / Book2.27
EPS-0.95
Book Value1.67
Revenue (TTM)3.61M
Gross Profit (TTM)3.35M
EBITDA-25.09M
Profit Margin0.00%
Operating Margin-1816.16%
Return on Equity-54.98%
Return on Assets-34.08%
Shares Outstanding18.21M
Shares Float14.28M
Beta-0.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 3 analystsTarget 13.25
  • Strong Buy
    1
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
2.07%
Insiders
0.00%
Retail / Other
97.93%

Top Institutional Holders

  • Twin Lakes Capital Management, LLC
    139.26K0.76%
  • Greenleaf Trust
    62.00K0.34%
  • HB Wealth Management, LLC
    58.46K0.32%
  • Morgan Stanley - Brokerage Accounts
    58.38K0.32%
  • Citadel Advisors Llc
    37.60K0.21%
  • BNP Paribas Arbitrage, SA
    6.81K0.04%
  • GAMMA Investing LLC
    2.31K0.01%
  • Rhumbline Advisers
    1.97K0.01%
  • Acadian Asset Management LLC
    1.86K0.01%
  • Providence Capital Advisors, LLC
    2000.00%
  • Integrated Wealth Concepts LLC
    730.00%
  • Advisor Group Holdings, Inc.
    680.00%
  • Ronald Blue Trust, Inc.
    400.00%
  • CoreCap Advisors, LLC
    210.00%
  • Steward Partners Investment Advisory, LLC
    60.00%
  • Cranbrook Wealth Management, LLC
    10.00%
  • Danske Bank A/S.
    10.00%
  • Tower Research Capital LLC
    00.00%
  • Citigroup Inc
    00.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    1.16K0.01%

Stock Splits

  • Jan 9, 20231:10
  • Mar 24, 20161:6